Illegal production of Ginkgo biloba extract by a pharmaceutical company in Guangxi

Illegal production of Ginkgo biloba extract by a pharmaceutical enterprise in Guangxi involving three pharmaceutical enterprises in our province has recalled more than 93 million tablets "I ran several drugstores, but I couldn't buy Ginkgo biloba (dispersive) tablets What's the matter?" recently, many citizens in Haikou reported that when they bought Ginkgo biloba drugs in drugstores, they were told that they were out of stock, and they may not be able to buy them in the near future, which made the citizens feel very strange It is understood that in mid May, the State Food and Drug Administration (hereinafter referred to as "the State Food and Drug Administration") found that Guangxi Guilin Xingda Pharmaceutical Co., Ltd illegally produced Ginkgo biloba extract in the inspection of enterprises selling Ginkgo biloba drugs at low prices Through investigation, it involves 26 ginkgo leaf drug manufacturers in China, including 3 in Hainan In response, the State Food and Drug Administration issued an urgent notice, demanding that the production and sale of Ginkgo biloba "problem" drugs be stopped immediately, and that the commercial Ginkgo biloba drugs within the full validity period be recalled As of July 13, Haikou Qili Pharmaceutical Co., Ltd and other three pharmaceutical companies in our province recalled 93.163214 "problem" drugs of Ginkgo biloba leaves Incident: illegal production of Guangxi pharmaceutical enterprises implicated many pharmaceutical enterprises in China On May 19, the State Food and Drug Administration issued the notice on illegal production and sale of ginkgo leaf drugs by Guilin Xingda Pharmaceutical Co., Ltd and other enterprises According to the notice, after preliminary investigation, Guilin Xingda Pharmaceutical Co., Ltd changed the production process of ginkgo leaf extraction from dilute ethanol extraction to 3% hydrochloric acid extraction At the same time, no qualified enterprise purchased ginkgo leaf extract produced by hydrochloric acid process for the production of ginkgo leaf, and sold the purchased extract to other pharmaceutical manufacturers, forged the purchase account of raw materials and Production inspection record Wan Bangde (Hunan) Natural Medicine Co., Ltd uses the Ginkgo biloba extract purchased to produce preparations such as Ginkgo biloba leaves and Ginkgo biloba capsules, and forges the purchase account of raw materials and production inspection records The two enterprises are suspected of violating the drug administration law of the people's Republic of China and the Pharmacopoeia of the people's Republic of China The food and drug regulatory authorities of Guangxi and Hunan provinces have filed a case for investigation The production of Ginkgo biloba extract by hydrochloric acid process can decompose the effective components of drugs and affect the efficacy of drugs In response, the State Food and drug administration requires that all operating and using units immediately stop selling and using ginkgo biloba drugs of Guilin Xingda Pharmaceutical Co., Ltd and WAN Bangde (Hunan) Natural Medicine Co., Ltd The food and drug regulatory authorities of Guangxi and Hunan provinces shall supervise the recall of all products on sale by enterprises, while the food and drug regulatory authorities of other provinces (regions and cities) shall supervise the enterprises and units in their respective administrative regions to do a good job in drug recall.